Tamsulosin controlled-release - Veru Healthcare

Drug Profile

Tamsulosin controlled-release - Veru Healthcare

Latest Information Update: 19 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aspen Park Pharmaceuticals
  • Developer Veru Healthcare
  • Class Small molecules; Sulfonamides
  • Mechanism of Action Alpha 1a adrenergic-receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Benign prostatic hyperplasia

Most Recent Events

  • 27 Jan 2016 Preclinical trials in Benign prostatic hyperplasia in USA (PO)
  • 27 Jan 2016 Aspen Park Pharmaceuticals plans a clinical trial for Benign prostatic hyperplasia (Aspen Park Pharmaceuticals pipeline)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top